Medtronic MDT
Medtronic is a global medical technology company that designs and manufactures devices and therapies to treat over 70 diseases, including cardiology, surgery, neurology, and diabetes. Medtronic presents a balanced profile: solid financial health (ND/EBITDA 1.86), revenue growth of 13.7%, and a reasonable valuation (forward P/E 13.84). The main challenge is the execution of its new bets in robotics and AI, which do not yet contribute significantly to results.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Medtronic is a global medical technology company that designs and manufactures devices and therapies to treat over 70 diseases, including cardiology, surgery, neurology, and diabetes. Medtronic presents a balanced profile: solid financial health (ND/EBITDA 1.86), revenue growth of 13.7%, and a reasonable valuation (forward P/E 13.84). The main challenge is the execution of its new bets in robotics and AI, which do not yet contribute significantly to results.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.1 |
| Quality / Moat | 6.0 |
| Valuation | 5.9 |
| Growth | 8.1 |
| Dividend | 6.9 |
| Momentum | 4.9 |
| Risk & Context | 7.8 |
OVERALL SCORE: 6.7/10
Context and risks
Moderate regulatory risk in the medical devices sector (price controls and FDA approvals). Domiciled in Ireland with moderate governance, although the business operates mainly in the US.
News considered in the analysis
- Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? — Listículo comparativo sin información nueva sobre Medtronic.
- Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? — Comparativa genérica entre dos empresas de sectores distintos; sin datos concretos que afecten a la valoración de MDT.
- Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets? — Artículo de análisis sobre la estrategia de crecimiento en nuevas áreas (robótica, IA) frente al negocio principal; sugiere un riesgo de ejecución moderado.
- Medtronic's High Dividend Yield Gets Little Attention on Wall Street -- Should You Buy the Stock Anyway? — Opinión sobre la atractividad del dividendo; sin información nueva sobre la empresa.
- Why Is Medtronic (MDT) Expanding In Robotics And AI Healthcare? — Noticia sobre la expansión en robótica e IA, un área de crecimiento potencial pero con incertidumbre sobre su contribución a beneficios a corto plazo.
Verdict: Hold. The combination of moderate growth, an attractive dividend, and a reasonable valuation offers a balanced risk/reward profile, though without clear short-term catalysts.
Main risk: Execution risk in new growth areas (robotics, AI) that may not offset the slowdown in core business units.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →